A Diabetes Drug May Help Prevent Lymphedema in Breast Cancer Survivors—Here's What the Research Shows

Researchers have identified two promising drug classes that may help prevent or treat breast cancer-related lymphedema (BCRL), a painful swelling condition affecting about 20% of breast cancer survivors. A comprehensive systematic review published in Frontiers in Oncology analyzed 24 clinical studies to evaluate which medications and herbal supplements could prevent or treat this long-term side effect. The findings suggest that glucagon-like peptide-1 receptor agonists (GLP-1 RAs)—drugs originally developed for diabetes—may reduce the risk of developing lymphedema, while immune-modulating therapies showed benefits for managing existing symptoms.

What Is Breast Cancer-Related Lymphedema and Why Does It Matter?

Breast cancer-related lymphedema occurs when lymph fluid accumulates in the arm, breast, or chest wall after cancer treatment, causing swelling, pain, and reduced mobility. Beyond the physical discomfort, BCRL creates significant financial and emotional burdens. Current treatment requires lifelong compression therapy or complete decongestive therapy (CDT), which is expensive, burdensome, and doesn't work equally well for everyone. Patients also face risks of recurrent infections and cellulitis, and many experience permanent disability that disrupts their work and finances.

Which Medications Showed Promise in the Research?

The systematic review, conducted by researchers at Ohio State University and Mayo Clinic, examined studies published between 1993 and 2025 investigating pharmacologic and herbal agents for BCRL prevention and treatment. Of 217 articles screened, 24 studies met inclusion criteria and were analyzed in detail.

The research team tested multiple drug categories to see if they could prevent or treat lymphedema:

• GLP-1 Receptor Agonists: These diabetes medications showed the most promise for prevention, with evidence suggesting they may reduce the risk of developing BCRL in the first place.
• Immunomodulatory Therapies: Drugs that modify immune function demonstrated improved signs and symptoms of BCRL in three studies, offering potential relief for patients already experiencing swelling and pain.
• Anti-inflammatory Medications: Nonsteroidal anti-inflammatory drugs (NSAIDs) and steroids showed no benefit for either prevention or treatment of BCRL.
• Other Drug Classes Tested: Anti-diabetic medications (thiazolidinediones), anti-hypertensive drugs, microbiome supplements, doxycycline, and herbal products either showed no effect or produced inconsistent results.

How Do GLP-1 Receptor Agonists Work for Lymphedema Prevention?

GLP-1 RAs are a class of medications that mimic a natural hormone in the body. While they're widely known for helping people with type 2 diabetes manage blood sugar and lose weight, the research suggests they may also reduce inflammation and fibrosis (scarring) in lymphatic tissue—key mechanisms underlying lymphedema development. The exact biological pathway remains under investigation, but the preliminary evidence is encouraging enough to warrant further study.

What Do Experts Say About Next Steps?

The research team emphasized that while these findings are promising, more rigorous testing is needed before these drugs can be recommended as standard prevention or treatment. "Rigorous prospective trials using standardized limb volume and edema measures, quality-of-life assessments, and symptom measures with longer follow-up are needed to inform clinical practice aimed at preventing and treating BCRL," the researchers noted.

Steps to Understanding Your Lymphedema Risk

• Know Your Risk Factors: About 20% of breast cancer survivors develop lymphedema, but risk varies based on the extent of lymph node removal, radiation therapy, and other individual factors. Ask your oncology team to assess your personal risk.
• Discuss Surveillance Options: Research shows that prospective surveillance models with early intervention can reduce BCRL incidence and severity, so ask whether your cancer center offers monitoring programs.
• Ask About Emerging Treatments: If you develop lymphedema or are at high risk, discuss with your doctor whether you might be eligible for clinical trials testing GLP-1 RAs or immunomodulatory therapies for BCRL.
• Explore Current Management: While waiting for new pharmacologic options, compression therapy and complete decongestive therapy remain first-line treatments, though insurance coverage varies by plan.

Why This Research Matters Now

Current BCRL management is limited by the burden and cost of lifelong compression therapy, variable effectiveness, and limited insurance coverage. Surgical prevention options like lymphatic reconstruction require specialized training and have limited long-term data. A safe, effective medication could transform care for breast cancer survivors by offering a preventive or therapeutic option that doesn't require daily compression garments or expensive therapy sessions.

The research team screened databases including PubMed, Embase, and Web of Science to ensure comprehensive coverage of the scientific literature. Three independent reviewers evaluated each study between June and August 2025 to minimize bias. The analysis focused on adult patients ages 18 and older with stage I-III breast cancer who either developed BCRL or were at risk for it following cancer treatment.

What Comes Next for Patients?

The findings have been registered with PROSPERO, an international database of systematic reviews, ensuring transparency and preventing duplicate research efforts. The next phase involves designing prospective clinical trials—the gold standard for testing whether GLP-1 RAs and immunomodulatory therapies actually prevent or treat BCRL in real-world patients. These trials will need to use standardized measurements of limb swelling, quality-of-life assessments, and symptom tracking over extended follow-up periods to provide definitive answers.

For breast cancer survivors currently managing lymphedema or worried about developing it, this research offers hope that new pharmacologic options may be on the horizon. In the meantime, working with your healthcare team to monitor for early signs of lymphedema and exploring available treatment options remains the best approach to managing this common complication.